June 13, 2025

RSV Vaccine Approved for Younger Adults

The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.

Conexiant

June 13, 2025

Obicetrapib May Offer LDL Benefit

In a randomized trial of more than 2,500 patients at high cardiovascular risk, obicetrapib significantly reduced low-density lipoprotein cholesterol levels when added to existing lipid-lowering therapy.

Conexiant

June 13, 2025

Weight Loss Drugs Show Promise for Heart Failure

ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.

Conexiant

June 13, 2025

Riva Returns!

Luigi Mondello explains why the time is right to reignite Chromatography’s much-missed “scientific retreat”

The Analytical Scientist

June 13, 2025

Experts: HHS Sent Congress ‘Junk Science’

A controversial HHS document supporting RFK Jr.'s rollback of COVID vaccine guidance relies on disputed or misrepresented science, prompting outrage from health experts who call it “willful medical disinformation.”

KFF Health News

June 13, 2025

Lifestyle Interventions Recommended First-Line in Diabetes

A new guideline recommends using lifestyle interventions as first-line treatment to prevent, manage, and potentially reverse type 2 diabetes and prediabetes, supported by extensive clinical evidence.

Conexiant

June 13, 2025

The Special Series HPLC E-book

Are we still pushing the limits of liquid chromatography? Absolutely, say our experts – who continue to surf on the edge of LC innovation – as part of our special collection of recent HPLC insights.

The Analytical Scientist

June 13, 2025

JAK Inhibitors Show No Increased Cancer Risk

New real-world data show no significant rise in overall cancer incidence with JAK inhibitors for rheumatoid arthritis patients, though skin cancer monitoring remains important.

Conexiant

June 13, 2025

SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC

Although the SWOG S2302 Pragmatica-Lung trial did not achieve its primary endpoint of improved overall survival with the combination of ramucirumab and pembrolizumab compared with standard-of-care tre...

The ASCO Post